Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis
Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA). This pr...
Gespeichert in:
| Veröffentlicht in: | Hepatobiliary & pancreatic diseases international 2020-06, Vol.19 (3), p.271-276 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 3 |
| container_start_page | 271 |
| container_title | Hepatobiliary & pancreatic diseases international |
| container_volume | 19 |
| creator | Gümüş Güler, Başak Özler, Sibel |
| description | Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA).
This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). The primary end points were the perinatal outcome and the response to UDCA therapy. A logistic regression model was used to identify the independent risk factors of adverse pregnancy outcomes and reduced response to UDCA therapy.
Women with ICP had significantly higher serum syndecan-1 (1.27 ± 0.36 ng/mL vs. 0.98 ± 0.50 ng/mL; P = 0.003), glypican-3 (1.78 ± 0.13 ng/mL vs.1.69 ± 0.16 ng/mL; P = 0.004), AST (128.59 ± 1.44 vs. 13.29 ± 1.32 U/L; P |
| doi_str_mv | 10.1016/j.hbpd.2019.12.001 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_gjgdybzz_z202003011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>gjgdybzz_z202003011</wanfj_id><els_id>S1499387219302516</els_id><sourcerecordid>gjgdybzz_z202003011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-de7a636d57e572b8d052b54386ff796e66187cddfb4ce008d4b3733560be3bc3</originalsourceid><addsrcrecordid>eNp9kU1r3DAQhn1oadI0fyCHomOh2NWHLcvQSwlpEwj0krvQx3hXxpZcSW7Y_fXVdpMeC4JBzDOvxDxVdUNwQzDhX6Zmr1fbUEyGhtAGY_KmuiTtMNRM9PSiep_ShDEVouPvqgtGBjJgJi6r5wdvIqgEFqWDt2CUrwlS3qLdfFjd6crQGsE6k9EaQkQrROdVVjMKWzZhgb90LiF5AZ9RhORSVt4Acr6cHNUeVpWdQWYfZii9Anyo3o5qTnD9Uq-qp-93T7f39ePPHw-33x5rw1qWawu94ozbroeup1pY3FHdtUzwcewHDpwT0RtrR90awFjYVrOesY5jDUwbdlV9Psc-Kz8qv5NT2KIvD8rdtLMHfTzKI8UUY4YJKfSnM73G8GsrP5WLSwbmWXkIW5KUMU47zlpRUHpGTQwpRRjlGt2i4kESLE9G5CRPRuTJiCRUFiNl6ONL_qYXsP9GXnUU4OsZgLKS3w6iTMZBWaV1EUyWNrj_5f8Bz3Ogrg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2336256348</pqid></control><display><type>article</type><title>Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gümüş Güler, Başak ; Özler, Sibel</creator><creatorcontrib>Gümüş Güler, Başak ; Özler, Sibel</creatorcontrib><description>Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA).
This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). The primary end points were the perinatal outcome and the response to UDCA therapy. A logistic regression model was used to identify the independent risk factors of adverse pregnancy outcomes and reduced response to UDCA therapy.
Women with ICP had significantly higher serum syndecan-1 (1.27 ± 0.36 ng/mL vs. 0.98 ± 0.50 ng/mL; P = 0.003), glypican-3 (1.78 ± 0.13 ng/mL vs.1.69 ± 0.16 ng/mL; P = 0.004), AST (128.59 ± 1.44 vs. 13.29 ± 1.32 U/L; P < 0.001), and ALT (129.84 ± 1.53 vs. 8.00 ± 3.67 U/L; P < 0.001) levels compared with the controls. The increased levels of syndecan-1 (OR = 4.715, 95% CI: 1.554–14.310; P = 0.006), glypican-3 (OR = 8.465, 95% CI: 3.372–21.248; P = 0.007), ALT (OR = 1.382, 95% CI: 1.131–1.690; P = 0.002), and postprandial bile acid (PBA) (OR = 3.392, 95% CI: 1.003–12.869; P = 0.026) were correlated to ICP. The adverse neonatal outcome was related to increased glypican-3 (OR = 4.275, 95% CI: 2.726–5.635; P = 0.039), and PBA (OR = 3.026, 95% CI: 1.069–13.569; P = 0.037). Increases of syndecan-1 (OR = 7.464, 95% CI: 2.130–26.153, P = 0.017) and glypican-3 (OR = 6.194, 95% CI: 2.951–13.002; P = 0.025) were the risk factors of decreased response to UDCA treatment.
Syndecan-1 and glypican-3 might be powerful determinants in predicting adverse perinatal outcome in patients with ICP, and they can be used to predict the response to the UDCA treatment.</description><identifier>ISSN: 1499-3872</identifier><identifier>DOI: 10.1016/j.hbpd.2019.12.001</identifier><identifier>PMID: 31919038</identifier><language>eng</language><publisher>Singapore: Elsevier B.V</publisher><subject>Adult ; Adverse perinatal outcome ; Alanine Transaminase - blood ; Apgar Score ; Aspartate-Ammonia Ligase - blood ; Bile Acids and Salts - blood ; Biomarkers - blood ; Birth Weight ; Case-Control Studies ; Cholagogues and Choleretics - therapeutic use ; Cholestasis, Intrahepatic - blood ; Cholestasis, Intrahepatic - drug therapy ; Female ; Glypican-3 ; Glypicans - blood ; Humans ; Intrahepatic cholestasis of pregnancy ; Postprandial Period ; Pregnancy ; Pregnancy Complications - blood ; Pregnancy Complications - drug therapy ; Premature Birth - blood ; Prospective Studies ; Response to UDCA ; Risk Factors ; Syndecan-1 ; Syndecan-1 - blood ; Ursodeoxycholic Acid - therapeutic use ; Young Adult</subject><ispartof>Hepatobiliary & pancreatic diseases international, 2020-06, Vol.19 (3), p.271-276</ispartof><rights>2020 First Affiliated Hospital, Zhejiang University School of Medicine in China</rights><rights>Copyright © 2020 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.</rights><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c343t-de7a636d57e572b8d052b54386ff796e66187cddfb4ce008d4b3733560be3bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/gjgdybzz-z/gjgdybzz-z.jpg</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.hbpd.2019.12.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31919038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gümüş Güler, Başak</creatorcontrib><creatorcontrib>Özler, Sibel</creatorcontrib><title>Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis</title><title>Hepatobiliary & pancreatic diseases international</title><addtitle>Hepatobiliary Pancreat Dis Int</addtitle><description>Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA).
This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). The primary end points were the perinatal outcome and the response to UDCA therapy. A logistic regression model was used to identify the independent risk factors of adverse pregnancy outcomes and reduced response to UDCA therapy.
Women with ICP had significantly higher serum syndecan-1 (1.27 ± 0.36 ng/mL vs. 0.98 ± 0.50 ng/mL; P = 0.003), glypican-3 (1.78 ± 0.13 ng/mL vs.1.69 ± 0.16 ng/mL; P = 0.004), AST (128.59 ± 1.44 vs. 13.29 ± 1.32 U/L; P < 0.001), and ALT (129.84 ± 1.53 vs. 8.00 ± 3.67 U/L; P < 0.001) levels compared with the controls. The increased levels of syndecan-1 (OR = 4.715, 95% CI: 1.554–14.310; P = 0.006), glypican-3 (OR = 8.465, 95% CI: 3.372–21.248; P = 0.007), ALT (OR = 1.382, 95% CI: 1.131–1.690; P = 0.002), and postprandial bile acid (PBA) (OR = 3.392, 95% CI: 1.003–12.869; P = 0.026) were correlated to ICP. The adverse neonatal outcome was related to increased glypican-3 (OR = 4.275, 95% CI: 2.726–5.635; P = 0.039), and PBA (OR = 3.026, 95% CI: 1.069–13.569; P = 0.037). Increases of syndecan-1 (OR = 7.464, 95% CI: 2.130–26.153, P = 0.017) and glypican-3 (OR = 6.194, 95% CI: 2.951–13.002; P = 0.025) were the risk factors of decreased response to UDCA treatment.
Syndecan-1 and glypican-3 might be powerful determinants in predicting adverse perinatal outcome in patients with ICP, and they can be used to predict the response to the UDCA treatment.</description><subject>Adult</subject><subject>Adverse perinatal outcome</subject><subject>Alanine Transaminase - blood</subject><subject>Apgar Score</subject><subject>Aspartate-Ammonia Ligase - blood</subject><subject>Bile Acids and Salts - blood</subject><subject>Biomarkers - blood</subject><subject>Birth Weight</subject><subject>Case-Control Studies</subject><subject>Cholagogues and Choleretics - therapeutic use</subject><subject>Cholestasis, Intrahepatic - blood</subject><subject>Cholestasis, Intrahepatic - drug therapy</subject><subject>Female</subject><subject>Glypican-3</subject><subject>Glypicans - blood</subject><subject>Humans</subject><subject>Intrahepatic cholestasis of pregnancy</subject><subject>Postprandial Period</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - blood</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Premature Birth - blood</subject><subject>Prospective Studies</subject><subject>Response to UDCA</subject><subject>Risk Factors</subject><subject>Syndecan-1</subject><subject>Syndecan-1 - blood</subject><subject>Ursodeoxycholic Acid - therapeutic use</subject><subject>Young Adult</subject><issn>1499-3872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1r3DAQhn1oadI0fyCHomOh2NWHLcvQSwlpEwj0krvQx3hXxpZcSW7Y_fXVdpMeC4JBzDOvxDxVdUNwQzDhX6Zmr1fbUEyGhtAGY_KmuiTtMNRM9PSiep_ShDEVouPvqgtGBjJgJi6r5wdvIqgEFqWDt2CUrwlS3qLdfFjd6crQGsE6k9EaQkQrROdVVjMKWzZhgb90LiF5AZ9RhORSVt4Acr6cHNUeVpWdQWYfZii9Anyo3o5qTnD9Uq-qp-93T7f39ePPHw-33x5rw1qWawu94ozbroeup1pY3FHdtUzwcewHDpwT0RtrR90awFjYVrOesY5jDUwbdlV9Psc-Kz8qv5NT2KIvD8rdtLMHfTzKI8UUY4YJKfSnM73G8GsrP5WLSwbmWXkIW5KUMU47zlpRUHpGTQwpRRjlGt2i4kESLE9G5CRPRuTJiCRUFiNl6ONL_qYXsP9GXnUU4OsZgLKS3w6iTMZBWaV1EUyWNrj_5f8Bz3Ogrg</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Gümüş Güler, Başak</creator><creator>Özler, Sibel</creator><general>Elsevier B.V</general><general>Department of Health Sciences, Istinye University, Istanbul 34010, Turkey%Department of Perinatology, Selcuk University Faculty of Medicine, Konya 42130, Turkey</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20200601</creationdate><title>Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis</title><author>Gümüş Güler, Başak ; Özler, Sibel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-de7a636d57e572b8d052b54386ff796e66187cddfb4ce008d4b3733560be3bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Adverse perinatal outcome</topic><topic>Alanine Transaminase - blood</topic><topic>Apgar Score</topic><topic>Aspartate-Ammonia Ligase - blood</topic><topic>Bile Acids and Salts - blood</topic><topic>Biomarkers - blood</topic><topic>Birth Weight</topic><topic>Case-Control Studies</topic><topic>Cholagogues and Choleretics - therapeutic use</topic><topic>Cholestasis, Intrahepatic - blood</topic><topic>Cholestasis, Intrahepatic - drug therapy</topic><topic>Female</topic><topic>Glypican-3</topic><topic>Glypicans - blood</topic><topic>Humans</topic><topic>Intrahepatic cholestasis of pregnancy</topic><topic>Postprandial Period</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - blood</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Premature Birth - blood</topic><topic>Prospective Studies</topic><topic>Response to UDCA</topic><topic>Risk Factors</topic><topic>Syndecan-1</topic><topic>Syndecan-1 - blood</topic><topic>Ursodeoxycholic Acid - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gümüş Güler, Başak</creatorcontrib><creatorcontrib>Özler, Sibel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Hepatobiliary & pancreatic diseases international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gümüş Güler, Başak</au><au>Özler, Sibel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis</atitle><jtitle>Hepatobiliary & pancreatic diseases international</jtitle><addtitle>Hepatobiliary Pancreat Dis Int</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>19</volume><issue>3</issue><spage>271</spage><epage>276</epage><pages>271-276</pages><issn>1499-3872</issn><abstract>Intrahepatic cholestasis of pregnancy (ICP) increases the risk of adverse pregnancy outcomes. This study aimed to explore the association between serum syndecan-1 and glypican-3 levels and the adverse perinatal outcome as well as the responses to the treatment of ursodeoxycholic acid (UDCA).
This prospective, case control study included 88 pregnant women (44 women with ICP and 44 healthy controls). The primary end points were the perinatal outcome and the response to UDCA therapy. A logistic regression model was used to identify the independent risk factors of adverse pregnancy outcomes and reduced response to UDCA therapy.
Women with ICP had significantly higher serum syndecan-1 (1.27 ± 0.36 ng/mL vs. 0.98 ± 0.50 ng/mL; P = 0.003), glypican-3 (1.78 ± 0.13 ng/mL vs.1.69 ± 0.16 ng/mL; P = 0.004), AST (128.59 ± 1.44 vs. 13.29 ± 1.32 U/L; P < 0.001), and ALT (129.84 ± 1.53 vs. 8.00 ± 3.67 U/L; P < 0.001) levels compared with the controls. The increased levels of syndecan-1 (OR = 4.715, 95% CI: 1.554–14.310; P = 0.006), glypican-3 (OR = 8.465, 95% CI: 3.372–21.248; P = 0.007), ALT (OR = 1.382, 95% CI: 1.131–1.690; P = 0.002), and postprandial bile acid (PBA) (OR = 3.392, 95% CI: 1.003–12.869; P = 0.026) were correlated to ICP. The adverse neonatal outcome was related to increased glypican-3 (OR = 4.275, 95% CI: 2.726–5.635; P = 0.039), and PBA (OR = 3.026, 95% CI: 1.069–13.569; P = 0.037). Increases of syndecan-1 (OR = 7.464, 95% CI: 2.130–26.153, P = 0.017) and glypican-3 (OR = 6.194, 95% CI: 2.951–13.002; P = 0.025) were the risk factors of decreased response to UDCA treatment.
Syndecan-1 and glypican-3 might be powerful determinants in predicting adverse perinatal outcome in patients with ICP, and they can be used to predict the response to the UDCA treatment.</abstract><cop>Singapore</cop><pub>Elsevier B.V</pub><pmid>31919038</pmid><doi>10.1016/j.hbpd.2019.12.001</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1499-3872 |
| ispartof | Hepatobiliary & pancreatic diseases international, 2020-06, Vol.19 (3), p.271-276 |
| issn | 1499-3872 |
| language | eng |
| recordid | cdi_wanfang_journals_gjgdybzz_z202003011 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Adverse perinatal outcome Alanine Transaminase - blood Apgar Score Aspartate-Ammonia Ligase - blood Bile Acids and Salts - blood Biomarkers - blood Birth Weight Case-Control Studies Cholagogues and Choleretics - therapeutic use Cholestasis, Intrahepatic - blood Cholestasis, Intrahepatic - drug therapy Female Glypican-3 Glypicans - blood Humans Intrahepatic cholestasis of pregnancy Postprandial Period Pregnancy Pregnancy Complications - blood Pregnancy Complications - drug therapy Premature Birth - blood Prospective Studies Response to UDCA Risk Factors Syndecan-1 Syndecan-1 - blood Ursodeoxycholic Acid - therapeutic use Young Adult |
| title | Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A32%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20syndecan-1%20and%20glypican-3%20predict%20poor%20perinatal%20outcome%20and%20treatment%20resistance%20in%20intrahepatic%20cholestasis&rft.jtitle=Hepatobiliary%20&%20pancreatic%20diseases%20international&rft.au=G%C3%BCm%C3%BC%C5%9F%20G%C3%BCler,%20Ba%C5%9Fak&rft.date=2020-06-01&rft.volume=19&rft.issue=3&rft.spage=271&rft.epage=276&rft.pages=271-276&rft.issn=1499-3872&rft_id=info:doi/10.1016/j.hbpd.2019.12.001&rft_dat=%3Cwanfang_jour_proqu%3Egjgdybzz_z202003011%3C/wanfang_jour_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2336256348&rft_id=info:pmid/31919038&rft_wanfj_id=gjgdybzz_z202003011&rft_els_id=S1499387219302516&rfr_iscdi=true |